Humatica, a private equity specialist adviser for portfolio organisational effectiveness, has advised private equity firm Intermediate Capital Group (ICG) on its investment in Lucid Group
Founded in 2007, Lucid Group is a strategic healthcare communications company committed to advancing patient health outcomes through healthcare communications that improve the way patients and diseases are managed, and medicines are used. Lucid Group’s pioneering approaches have received industry-wide recognition and have consistently led to above industry growth.
With offices in the UK, US and Asia, Lucid now employs around 250 people. Lucid works in partnership with the world’s leading pharmaceutical and biotech organisations and has played a pivotal role in providing healthcare communication solutions for many of the industry’s innovative blockbuster assets.
Humatica was engaged by ICG to provide Organisational Due Diligence advice for this transaction.
Source: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.